TITLE

Probiotics for Crohn's disease: what have we learned?

AUTHOR(S)
Prantera, C.
PUB. DATE
June 2006
SOURCE
Gut;Jun2006, Vol. 55 Issue 6, p757
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article analyzes the therapeutic use of probiotics for patients afflicted with Crohn's disease, either in the acute phase or for maintenance. It was observed that the intestinal flora is the essential factor in triggering the Crohn's inflammatory process in genetically prone patients. Thus immunosuppressors are used to reduce the host response and antibiotics are used to suppress the bacterial flora, with a consequent decreased activation of the gut immune system. It is suggested that theoretically it would be better to remove the harmful cause instead of curtailing the host defenses by inducing a form of immunodeficiency that is prone to opportunistic infections.
ACCESSION #
22212734

 

Related Articles

  • Immunosuppressant Medications and Mortality in Inflammatory Bowel Disease. Lewis, James D.; Gelfand, Joel M.; Troxel, Andrea B.; Forde, Kimberly A.; Newcomb, Craig; Kim, Hopiy; Margolis, David J.; Strom, Brian L. // American Journal of Gastroenterology;Jun2008, Vol. 103 Issue 6, p1428 

    OBJECTIVE: This study examined whether treatment of Crohn's disease (CD) and ulcerative colitis (UC) with immunosuppressant medications was associated with an increased risk of death in the era prior to antitumor necrosis factor (TNF) therapies. DESIGN: This retrospective cohort study used data...

  • Antibiotics Associated With Increased Risk of New-Onset Crohn's Disease But Not Ulcerative Colitis: A Meta-Analysis. Ungaro, Ryan; Colombel, Jean-Frédéric; Atreja, Ashish; Bernstein, Charles N; Shaw, Souradet; Gearry, Richard; Hviid, Anders; Kolho, Kaija-Leena; Kronman, Matthew P; Van Kruiningen, Herbert // American Journal of Gastroenterology;Nov2014, Vol. 109 Issue 11, p1728 

    OBJECTIVES:The objective of this study was to perform a meta-analysis investigating antibiotic exposure as a risk factor for developing inflammatory bowel disease (IBD).METHODS:A literature search using Medline, Embase, and Cochrane databases was performed to identify studies providing data on...

  • Roseburia hominis: a novel guilty player in ulcerative colitis pathogenesis? Tilg, Herbert; Danese, Silvio // Gut;Aug2014, Vol. 63 Issue 8, p1204 

    The article presents comments of the author on pathogenesis of ulcerative colitis. Topics discussed include role for intestinal bacteria in Crohn's Disease (CD) for improving of disease during antibiotic therapy, recovery of Faecalibacterium prausnitzii after disease relapse in ulcerative...

  • Fenotipo e historia natural de la enfermedad inflamatoria intestinal en un centro de referencia en Medell�n-Colombia. Ba�os, Fabi�n Juliao; V�lez, Mario Hern�n Ruiz; Arango, Jos� Fernando Fl�rez; G�mez, Jorge Hernando Donado; Zuluaga, Juan Ignacio Mar�n; Arango, Claudia Monsalve; G�mez, Carlos Andr�s Jim�nez; Zapata, Yineth Agudelo; Velayos, Fernando S. // Revista Colombiana de Gastroenterolog�a;Jul2012, Vol. 25 Issue 3, p240 

    Worldwide the frequencies of inflammatory bowel disease, ulcerative colitis and Crohn�s disease have all increased. In our own environment it has become necessary to establish the epidemiology of these entities and to determine their clinical and endoscopic behavior. Methodology: This is a...

  • In siblings with similar genetic susceptibility for inflammatory bowel disease, smokers tend to develop Crohn's disease and non-smokers develop ulcerative colitis. Bridger, S.; Lee, J.C.W.; Bjarnason, I.; Lennard Jones, J.E.; Macpherson, A.J. // Gut;Jul2002, Vol. 51 Issue 1, p21 

    Background and aims: Smoking tobacco has opposite effects on the different forms of inflammatory bowel disease (IBD). It predisposes to the development of Crohn's disease (CD) yet is associated with a reduced incidence of ulcerative colitis (UC). We have studied sib pairs discordant for both...

  • Inflammatory bowel disease. O'Malley, John; Spinks, Julian // Pulse;5/25/2011, Vol. 71 Issue 19, p16 

    The article presents questions and answers related to irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD), including the diagnostic process of IBD, what drug therapy to treat Crohn's disease, and the risk of cancer with ulcerative colitis.

  • Inflammatory bowel diseases.  // Mayo Clinic Health Letter;Oct2001, Vol. 19 Issue 10, p1 

    Discusses inflammatory bowel diseases. Etiology; Difference between Crohn's disease and ulcerative colitis; Signs and symptoms; Diagnostic techniques; Cancer risks; Treatment strategies. INSET: Colon cancer risks..

  • Kallikrein-kinin system activation in Crohn’s disease: differences in intestinal and systemic markers Devani, Massimo; Cugno, Massimo; Vecchi, Maurizio; Ferrero, Stefano; Di Berardino, Federica; Avesani, Ettore Contessini; de Franchis, Roberto; Colman, Robert W. // American Journal of Gastroenterology;Aug2002, Vol. 97 Issue 8, p2026 

    OBJECTIVES:Observations in experimental models and in human ulcerative colitis suggest that activation of the kallikrein-kinin system plays a role in the pathogenesis of inflammatory bowel disease. The aim of this study was to assess activation of the plasma and tissue kallikrein-kinin system in...

  • Unlocking the secrets of IBD. SerVaas, Cory // Saturday Evening Post;Jan/Feb94, Vol. 266 Issue 1, p42 

    Presents interviews with seven inflammatory disease specialists. Case for cyclosporine; Tracing genetic links; Choosing the right treatment; Longevity, pregnancy and new drugs; Alternatives to lleostomy; Iron and IBD; What causes IBD? INSETS: Now in remission, by Patrick Perry.;A cse of the...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sign out of this library

Other Topics